Replies to post #172436 on Biotech Values

[goodJohnhunting]

if PS is so promising a target and bavituximab hits it, then why hasn't there been any compelling clinical data to date

Mcbio, I do realize that many drugs make it to P3 trials, and like Bavituximab, they are designated fast track. However, isn't it an achievement to be granted passage to Phase 3?. At least they have a shot, and we'll finally know once and for all if targeting PS is therapeutic. It's obviously put up or shut up time for Peregrine, IMO.

While other drugs are oftentimes scrapped at earlier stages, it seems that Bavituximab trials have been compelling enough to continue. Signals have been made, and safety known.

Regarding the science, I've made numerous post challenging Anti-PS. I've theorized that Bavituximab loses it's ability to stay bound long enough for therapeutic benefit. I've theorized that phosphatidylserine's roll in cell signaling, coagulation and normal apoptotic cycle may be substantial, but blocking it may be inconsequential. I've posted how and why for many of my theories, but for what ever reason I'm still intrigued by the possibilities.

All the best,
John